research La combinación de finasteride y doxazosina fue más efectiva que la monoterapia en la hiperplasia prostática benigna
Using finasteride and doxazosina together works better for treating benign prostatic hyperplasia than using just one.
Search
for
Sort by
Research
780-810 / 1000+ results
research (379) The Effect of 5-α Reductase Inhibitor on Male Reproductive Function
5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.
research Platelet-Rich Plasma for Urologic Conditions: An Early Call for Composition Reporting
The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.
research SAT-279 The Effect of Chronic 5-alpha Reductase Inhibition on Clinically Apparent and Silent Cardiovascular Events
Finasteride lowers cholesterol but doesn't reduce heart-related events.
research 5‐Alpha reductase inhibitor related litigation: A legal database review
Most legal cases about 5α-reductase inhibitors, drugs for hair loss and prostate issues, complain about side effects and delayed cancer diagnosis, with most lawsuits settled out of court.
research Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement
5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.
research Finasteride/tamsulosin
Man stopped medications due to sexual side effects, found relief with prostatic artery embolisation.
research Suicidal ideation in patients undergoing treatment with 5α-reductase inhibitors
Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.
research Doxazosin + finasteride in BPH with TPV ??? 25mL
research Asociación entre disfunción eréctil y funcionalidad del subsistema conyugal en pacientes con hiperplasia prostática benigna
Erectile dysfunction is linked to marital issues in patients with benign prostatic hyperplasia.
research The role of dutasteride in the treatment of benign prostatic obstruction and related conditions
Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
research 332 FINASTERIDE FOR RECURRENT PRIAPISM IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE (SCD). REPORT OF 5 CASES
Finasteride effectively reduced priapism episodes in children with sickle cell disease without side effects.
research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly l-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from
Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.
research Role of 5α-reductase inhibitors in androgen-stimulated skin disorders.
5α-reductase inhibitors like finasteride and dutasteride can help treat skin disorders stimulated by androgens, such as hair loss and acne.
research (122) Erectile Hemodynamics Asessment In ED Patients With Self-Diagnosed Post-finasteride syndrome (PFS)
Men with self-diagnosed PFS-related ED have normal erectile hemodynamics.
research No increased risk of CV events with dutasteride vs finasteride
Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.
research Comparison of clinical trials with finasteride and dutasteride.
Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
research Eficacia de la combinación de doxazosina y finasterida en la hipertrofia benigna de próstata
Combining doxazosin and finasteride is more effective for managing benign prostatic hyperplasia than using either drug alone.
research Discovery of novel 5α-reductase type II inhibitors by pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulations
A new compound may treat benign prostatic hyperplasia better than finasteride.
research COMPARISON OF FINASTERIDE AND ALPHA‐BLOCKERS AS INDEPENDENT RISK FACTORS FOR ERECTILE DYSFUNCTION
Age and other health issues affect erectile dysfunction more than finasteride or alpha-blockers.
research Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
research Drug–DrugCoamorphous System of Tadalafil andFinasteride for Enhanced Pharmaceutical Performance
A new combination of tadalafil and finasteride improves drug performance and stability.
research ChemInform Abstract: Discovery of a Novel Hybrid from Finasteride and Epristeride as 5α‐Reductase Inhibitor.
A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
research 5ARI and PSA: open questions
5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
research Beeinflussen Medikamente gegen das benigne Prostatasyndrom Stimmung oder Kognition?
Medications for benign prostatic syndrome can cause cognitive issues and depression.
research In Vivo Time-Dependent Inhibition of Human Steroid 5a-Reductase by Finasteride
Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
research Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID ‐19 pandemic?
5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
research Re: Association of Treatment with 5α-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer
Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.